Neuspera Medical Inc.

Neuspera is looking forward to participating and presenting at the Piper Sandler 36th Annual Healthcare Conference early December. Steffen Hovard will provide an update on the progress and positive momentum for Neuspera in getting PMA approval for our micro-invasive system for treatment of overactive bladder. #PSCHealthcare2024 #OAB #Urology #Innovation

Neuspera CEO Steffen Hovard talks activity and alignment with Medsider. https://lnkd.in/gixvKDf8 #NeusperaSystem #neuromodulation #medicaldevice #incontinence

We are excited that the September 2024 issue of Urology Times included an update on the progress of our SANS UUI clinical trial. https://lnkd.in/gpakHCjY #NeusperaSystem #urology #incontinence #neuromodulation

We're live in DC at AUGS! Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel are excited to meet with key physicians and researchers at American Urogynecologic Society PFD Week as we gear up for our planned U.S. market introduction of the Neuspera System to treat symptoms of OAB in 2025. Hope to see you here!  #PFDweek #NeusperaSystem #urology #incontinence #neuromodulation

Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel will be heading to Washington D.C. for this year’s American Urogynecologic Society PFD Week and are looking forward to connecting with old friends and meeting new ones. Reach out via LinkedIn or email to meet up. Hope to see you there!    #PFDweek #NeusperaSystem #urology #incontinence #neuromodulation

The MedTech Conference is officially underway and it’s been an energizing week so far here in Toronto! Among the many fantastic presentations and panel discussions happening, our very own CEO Steffen Hovard participated in the engaging “MedTech Innovator Showcase: Urology Tech - Urine Luck” yesterday alongside a group of terrific panelists, including David N Constantine, Souvik Paul and Jeff Erb. Thanks to Abigail Hunter-Syed for moderating such a great conversation.     #MedTechCon #MTC24 #NeusperaSystem #OAB #urology #neuromodulation #medicaldevice #incontinence

We are happy to be part of the amazing AdvaMed community and participate at The Medtech Conference in Toronto October 15-17. #MedTechCon #OAB #Neuromodulation #urology #innovation

Did you know that this week is Urology Week 2024? To commemorate the occasion, MassDevice published an article on the top 10 urology device stories of 2024 so far and it featured our Series D round! Check it out, along with the other top stories of the year so far: https://lnkd.in/escJrR8w.   #NeusperaSystem #OAB #urology #neuromodulation #medicaldevice #incontinence

We are thrilled to welcome Bunty Banerjee as our first-ever chief operating officer! Bunty comes to us with deep medical device leadership experience and will lead activities in both research and development, as well as operations, while working closely with all other functions as we complete the FDA submission for regulatory approval of the Neuspera System to treat OAB symptoms and prepare for commercialization.    Read more about this exciting news over at the Neuspera website: https://lnkd.in/gnf3kwpC.   #NeusperaSystem #OAB #urology #incontinence #neuromodulation #newemployee

We’re excited to welcome two new members to our Neuspera team: Douglas Sullivan as Supply Chain Director and Jeff Siegel, CPA as Controller. We are grateful to have their expertise on the team as we continue working to improve sacral neuromodulation options for treating OAB! #OAB #urology #incontinence #neuromodulation #newemployee